Adaptive TONIC trial of nivolumab combinations for breast cancer

Dr Kok speaks with ecancer at ESMO 2017 about early results from TONIC, an adaptive phase II trial of nivolumab after induction for triple negative breast cancer patients. She outlines the five arms of the trial, and early results from the 55 patients randomised so far, with an overall response rate so far of 24%. More from ESMO 2017 : http://ecancer.org/conference/722-esm... Ecancer website: http://ecancer.org/video/index.php Twitter: @ecancer Facebook:   / ecancer